Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma

References

• Sarkozy C, Sehn LH. Management of relapsed/refractory DLBCL. Best Pract Res Clin Haematol. 2018;31(3):209–216.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–1861.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690.
   PubMed Web of Science ®Google Scholar
• Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481.e15–494.e15.
   Web of Science ®Google Scholar
• Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551.e14–568.e14.
   Web of Science ®Google Scholar
• Berendsen MR, Stevens WBC, van den Brand M, et al. Molecular genetics of relapsed diffuse large B-cell lymphoma: insight into mechanisms of therapy resistance. Cancers. 2020;12(12):3553.
   PubMed Web of Science ®Google Scholar
• Melchardt T, Hufnagl C, Weinstock DM, et al. Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. Oncotarget. 2016;7(32):51494–51502.
   PubMedGoogle Scholar
• Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an international DLBCL Rituximab-CHOP consortium program study. Blood. 2012;120(19):3986–3996.
   PubMed Web of Science ®Google Scholar
• Zainuddin N, Berglund M, Wanders A, et al. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. Leuk Res. 2009;33(1):60–66.
   PubMed Web of Science ®Google Scholar
• Lo Coco F, Gaidano G, Louie DC, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood. 1993;82(8):2289–2295.
   PubMed Web of Science ®Google Scholar
• Liu J, Dang H, Wang XW. The significance of intertumor and intratumor heterogeneity in liver cancer. Exp Mol Med. 2018;50(1):e416–e416.
   PubMedGoogle Scholar
• Ellsworth RE, Blackburn HL, Shriver CD, et al. Molecular heterogeneity in breast cancer: state of the science and implications for patient care. Semin Cell Dev Biol. 2017;64:65–72.
   PubMed Web of Science ®Google Scholar
• De Sousa VML, Carvalho L. Heterogeneity in lung cancer. Pathobiology. 2018;85(1-2):96–107.
   PubMed Web of Science ®Google Scholar
• Raynaud F, Mina M, Tavernari D, et al. Pan-cancer inference of intra-tumor heterogeneity reveals associations with different forms of genomic instability. PLoS Genet. 2018;14(9):e1007669.
   PubMed Web of Science ®Google Scholar
• Matolcsy A, Schattner EJ, Knowles DM, et al. Clonal evolution of B cells in transformation from low- to high-grade lymphoma. Eur J Immunol. 1999;29(4):1253–1264.
   PubMed Web of Science ®Google Scholar
• Carlotti E, Wrench D, Matthews J, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood. 2009;113(15):3553–3557.
   PubMed Web of Science ®Google Scholar
• Lee B, Lee H, Cho J, et al. Mutational profile and clonal evolution of relapsed/refractory diffuse large B-cell lymphoma. Front Oncol. 2021 Mar 11;11:628807. doi: 10.3389/fonc.2021.628807. eCollection 2021.
   Google Scholar
• Jiang Y, Redmond D, Nie K, et al. Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biol. 2014;15(8):432.
   PubMed Web of Science ®Google Scholar
• Schejbel L, Breinholt MF, Gang AO, et al. Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: strong correlation with BCL2 translocation. EJHaem. 2022;3(3):936–939.
   PubMedGoogle Scholar
• Izevbaye I, Liang LY, Mather C, et al. Clinical validation of a myeloid next-generation sequencing panel for single-nucleotide variants, insertions/deletions, and fusion genes. J Mol Diagn. 2020;22(2):208–219.
   PubMed Web of Science ®Google Scholar
• Schejbel L, Novotny GW, Breinholt MF, et al. Improved variant detection in clinical myeloid NGS testing by supplementing a commercial myeloid NGS assay with custom or extended data filtering and accessory fragment analysis. Mol Diagn Ther. 2021;25(2):251–266.
   PubMed Web of Science ®Google Scholar
• Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19​(1):​4–23.
   PubMed Web of Science ®Google Scholar
• Kopanos C, Tsiolkas V, Kouris A, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35(11):1978–1980.
   PubMed Web of Science ®Google Scholar
• Bouaoun L, Sonkin D, Ardin M, et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat. 2016;37(9):865–876.
   PubMed Web of Science ®Google Scholar
• Young KH, Leroy K, Møller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 2008;112(8):3088–3098.
   PubMed Web of Science ®Google Scholar
• Rushton CK, Arthur SE, Alcaide M, et al. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Adv. 2020;4(13):2886–2898.
   PubMed Web of Science ®Google Scholar
• Morin RD, Assouline S, Alcaide M, et al. Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin Cancer Res. 2016;22(9):2290–2300.
   PubMed Web of Science ®Google Scholar
• Shouval R, Tomas AA, Fein JA, et al. Impact of TP53 genomic alterations in large B-cell lymphoma treated With CD19-chimeric antigen receptor T-cell therapy. J Clin Oncol. 2022;40(4):369–381.
   PubMed Web of Science ®Google Scholar
• Araf S, Korfi K, Bewicke-Copley F, et al. Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. Haematologica. 2020;105(6):318–321.
   PubMed Web of Science ®Google Scholar
• Araf S, Wang J, Korfi K, et al. Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Leukemia. 2018;32(5):1261–1265.
   PubMed Web of Science ®Google Scholar
• Magnes T, Wagner S, Thorner AR, et al. Spatial heterogeneity in large resected diffuse large B-cell lymphoma bulks analysed by massively parallel sequencing of multiple synchronous biopsies. Cancers. 2021;13​(4):650.
   PubMed Web of Science ®Google Scholar
• Severson EA, Haberberger J, Hemmerich A, et al. Genomic profiling reveals differences in primary central nervous system lymphoma and large B-cell lymphoma, with subtyping suggesting sensitivity to BTK inhibition. Oncologist. 2023;28(1):e26–e35.
   PubMed Web of Science ®Google Scholar
• Ollila TA, Olszewski AJ. Extranodal diffuse large B cell lymphoma: molecular features, prognosis, and risk of central nervous system recurrence. Curr Treat Options Oncol. 2018; Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8.
   PubMed Web of Science ®Google Scholar
• Weissinger SE, Dugge R, Disch M, et al. Targetable alterations in primary extranodal diffuse large B-cell lymphoma. EJHaem. 2022;3(3):688–697.
   PubMedGoogle Scholar
• Regazzo G, Marchesi F, Spagnuolo M, et al. Diffuse large B-cell lymphoma: time to focus on circulating blood nucleic acids? Blood Rev. 2021;47.
   PubMed Web of Science ®Google Scholar
• Hou Y, Zi J, Liu S, et al. Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: based on next generation sequencing. Mol Carcinog. 2023;62(2):200–209.
   PubMedGoogle Scholar
• Rossi D, Spina V, Bruscaggin A, et al. Liquid biopsy in lymphoma. Haematologica. 2019;104(4):648–652.
   PubMed Web of Science ®Google Scholar